DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at Lake Street Capital in a research report issued on Friday, Benzinga reports. They currently have a $0.63 price target on the stock. Lake Street Capital’s target price suggests a potential downside of 2.17% from the stock’s previous close. A […]

Related Keywords

United States , Switzerland , Swiss , , Nasdaq , Dermtech Inc , Jpmorgan Chase Co , Centaurus Financial Inc , Charles Schwab Investment Management Inc , Swiss National Bank , Get Free Report , Lake Street Capital , Street Capital , Schwab Investment Management , National Bank , Dermtech Melanoma Test , Dermtech Daily , Dermtech , Nasdaq Dmtk , Dmtk , Medical , Reiterated Rating ,